
oct pm et
summari diversifi technolog compani provid advanc scientif technic product
servic world-wide pharmaceut industri market
price-to-earnings oper ep
risk assess reflect broad product mix
divers global client base howev compani
activ restructur busi unit product
portfolio well pursu acquisit could
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep stock trade
expect sale includ
acquisit immun medic laboratori
tulip diagnost rise
billion follow rise
account may sale medic
imag unit report segment
diagnost discoveri analyt
solut within diagnost see solid
growth screen busi strong
newborn prenat sale growth particularli
eastern europ china stabil
 within discoveri analyt
solut expect biopharmaceut
food safeti demand drive growth
medic laboratori ag billion immun
base germani lead diagnost
compani focus autoimmun infecti
diseas allergi test expect
deal accret ep
also activ restructur portfolio
increas invest see
oper margin improv basi point
look cost account
sale
think share trade
forward ep estim
slightli peer near high end
compani five-year averag
near fair valu yet see
continu benefit years-long
portfolio restructur higher-margin
high-growth market strateg effort
intern expans note
last four quarter sale grew organ
everi end market everi region oper
first time five year
aggress expand footprint china
meet demand prenat neonat
infecti diseas screen open new
clinic test lab think china
import growth market account
sale see
percentag grow next sever
year also see increas focu india
declin instrument sale slow growth
diagnost end market import
growth market particularli china india
target base
slightli peer forward
ep estim near high
end five-year rang
oct ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice presid
senior vice-president
corpor overview inc provid technolog servic solut
diagnost research environment safeti secur industri laboratori servic market
compani oper two segment diagnost discoveri analyt solut
diagnost segment focus develop diagnost tool applic help detect diseas
earlier acceler discoveri develop critic new therapi compani serv
diagnost research market product servic address genet screen
bio-discoveri market provid earli detect genet disord pre-concept earli
childhood well medic imag diagnost market product design provid
insight health expect mother pregnanc newborn compani
instrument reagent softwar test screen disord diseas includ syndrom
infertil anemia diabet compani medic imag detector use enabl doctor
make diagnos condit rang broken bone reduc blood flow vascular system
addit detector improv oncolog treatment focus radiat directli tumor
research market provid suit solut includ reagent liquid handl detect
technolog enabl research improv drug discoveri process applic solut
servic enabl pharmaceut compani creat therapeut portfolio liquid handl
detect technolog includ rang system consist instrument autom
detect solut cellular imag analysi hardwar softwar
addit compani portfolio consum product includ drug discoveri research
reagent sell research solut pharmaceut biotechnolog academ research
discoveri analyt solut segment serv environment food industri life scienc
research laboratori servic market environment market compani develop
provid analyt technolog solut servic enabl custom understand
character health variou aspect environ includ air water soil
compani technolog use detect help reduc impact product industri process
might environ provid tool need test function meet qualiti
specif safeti standard innov next gener product
food market compani provid variou solut help farmer food produc provid
popul food safe nutriti instrument confirm food qualiti includ level
moistur grain level fat butter compani instrument also use detect
presenc potenti danger contamin lead mercuri milk solut could also
use identifi origin food product oliv oil help prevent counterfeit
compani method analys transfer throughout suppli chain
industri market compani provid analyt instrument chemic electron
energi lubric petrochem polym industri industri instrument primarili use
custom focus qualiti assur standard
life scienc research market compani provid suit solut includ reagent
informat detect imag technolog enabl scientist improv life scienc
research facilit drug discoveri process product solut servic support
pharmaceut biotech compani well academ institut intern creat
therapeut help bring product market compani research portfolio includ rang
system consist imag detect extract instrument use vitro ex vivo
vivo model analysi hardwar softwar well rang consum product includ drug
discoveri research reagent
compani also provid servic design enabl custom laboratori servic market
world-wide activ restructur product portfolio recent year
impact major develop acquisit help restructur product portfolio
geospiza inc cambridgesoft corpor artu lab chemagen biopolymertechnologi ag
purchas follow seven acquisit three divestitur acquir
shanghai haoyuan biotech decemb acquir perten instrument ab june
acquir april sold perkinelm lab eurofin scientif decemb
acquir immun medic laboratori lead diagnost compani focus autoimmun
infecti diseas allergi test januari acquir india-bas tulip diagnost
financi trend sale grown billion billion repres
modest three-year compound annual growth rate compound-annual-growth-rate sale impact sever
acquisit well divestitur time period adjust ep increas
repres three-year compound-annual-growth-rate
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
lst sub-industri
next month think among
fastest-grow sub-industri within health
care sector driver earn growth
sub-industri next year
view strong growth public fund
health care research increas
spend biopharmaceut compani
budget nation institut
nih grown rapidli last three
year materi increas fund
academ govern lab turn
drive sale growth lst compani
view sub-industri deriv materi
portion revenu lab fy
nih budget grew
fy
think budget increas aid
lst sub-industri sale growth
estim
expect increas public fund support
robust demand sub-industri
product come year well
addit public-fund health care
research expect larg increas privat
biopharmaceut spend drive sale
growth life scienc tool servic
sub-industri year end june
estim spend
increas year-over-year
spend biotech
compar estim annual increas
pharma respect
year end june think
acceler spend translat
solid sale growth life scienc
tool servic sub-industri
depart research tool product
well contract research servic
clinic drug trial see type growth
continu year ahead
beyond biopharmaceut custom
believ health care research type
prolifer around world particularli
china emerg market turn
drive strong intern sale growth
establish life scienc tool servic
compani view china
particular use five largest compani
sub-industri proxi estim
sub-industri sale chines
custom grown
versu prior-year period compar
total revenu growth
think china certain emerg market
nation need continu rapidli increas
health care expenditur parallel
grow middl class turn
continu support strong sale growth
see happen despit threat
import/export tariff believ
limit large-scal supplier option
state-of-the-art lst product outsid
compani one notabl except
 life scienc tool
servic rose vs rise
 composit index year date
octob life
scienc tool servic index risen
vs rise
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
keep target ep
estim roughli line peer averag ep vs
consensu lower ep estim
keep show strong total revenu
growth yoy aid acquisit immun
post encourag organ revenu growth sinc close
exclud acquisit total organ revenu growth strong yoy
experienc broad-bas growth particularli robust demand drug
discoveri equip biopharma firm well immunodiagnost
appli genom end market howev adjust pre-tax incom keep
pace revenu growth yoy due higher sg margin
interest debt think improv margin
work year immun integr still feel stock
organ growth driven robust increas diagnost strong
emerg market demand discoveri analyt sale rose
encourag broad-bas growth first time year grew
organ everi end-market everi region world /jeffrey loo
rais target price in-lin
peer forward ep estim ep vs
line estim rais ep
estim anticip sale aid
new product launch improv end-market improv
sale rose discoveri analyt solut sale flat diagnost
sale although sale slightli forecast encourag
expans oper margin /jeffrey loo cfa
rais target slightli
peer estim although encourag
improv growth rate still peer averag
ep vs ahead estim sale rose
forecast sale growth pki best quarterli sale growth
sinc discoveri analyt sale rose diagnost sale rose
activ restructur product portfolio increas
invest acquisit drive long term growth
rais target slightli peer
forward ep estim near high end
five-year rang ep vs ahead
view rais ep estim ep
estim sale aid acquisit rose
organ growth healthi segment discoveri analyt
solut rose organ growth diagnost rose
organ growth discoveri analyt sale driven strong consum
uptak new imag analyt instrument within diagnost
sale driven signific growth emerg market aid
acquisit tulip euroimmun grew mid-teen
encourag signific oper margin expans basi point
aid supplier consolid follow basi point
declin /jeffrey loo cfa
et cfra keep hold opinion share inc
keep target price slightli
peer ep estim valuat
near high-end five-year rang encourag
organ sale growth aid portfolio restructur ep
vs ahead estim sale aid acquisit rose
organ growth diagnost repres
sale grew organ growth discoveri analyt solut
sale rose sale life scienc market account
sale rose organ growth sale appli market
includ industri food environment market rose
organ growth third consecut quarter organ growth
everi end market howev note oper margin declin bp
look lower cost consolid supplier collabor
rais target ep
estim slightli peer high-end
five-year rang set ep ep
vs ahead estim sale rose organ
growth second consecut quarter organ revenu growth
everi end market everi region world encourag
portfolio restructur believ recent acquisit euroimmun
tulip strengthen offer china europ india /jeffrey loo
rais target in-lin peer
forward ep estim ep vs
ahead estim lower ep estim
rais ep estim sale rose
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
